Glyxambi (Boehringer Ingelheim Pharmaceuticals, Inc.)
Welcome to the PulseAid listing for the Glyxambi drug offered from Boehringer Ingelheim Pharmaceuticals, Inc.. This Sodium-Glucose Cotransporter 2 Inhibitor [EPC],Sodium-Glucose Transporter 2 Inhibitors [MoA],Dipeptidyl Peptidase 4 Inhibitors [MoA],Dipeptidyl Peptidase 4 Inhibitor [EPC] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | Boehringer Ingelheim Pharmaceuticals, Inc. |
| NON-PROPRIETARY NAME: | empagliflozin and linagliptin |
| SUBSTANCE NAME: | EMPAGLIFLOZIN; LINAGLIPTIN |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | Sodium-Glucose Cotransporter 2 Inhibitor [EPC],Sodium-Glucose Transporter 2 Inhibitors [MoA],Dipeptidyl Peptidase 4 Inhibitors [MoA],Dipeptidyl Peptidase 4 Inhibitor [EPC] |
| ROUTE: | ORAL |
| DOSAGE FORM: | TABLET, FILM COATED |
| MARKETING CATEGORY NAME: | NDA |
| START MARKETING DATE: | 2015-01-30 |
| END MARKETING DATE: | 0000-00-00 |
Glyxambi HUMAN PRESCRIPTION DRUG Details:
| Item Description | Glyxambi from Boehringer Ingelheim Pharmaceuticals, Inc. |
| LABELER NAME: | Boehringer Ingelheim Pharmaceuticals, Inc. |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 25; 5(mg/1; mg/1) |
| START MARKETING DATE: | 2015-01-30 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 0597-0164_8249f6e0-2ede-9228-c646-2728ed57c524 |
| PRODUCT NDC: | 0597-0164 |
| APPLICATION NUMBER: | NDA206073 |
Other EMPAGLIFLOZIN; LINAGLIPTIN Pharmaceutical Manufacturers / Labelers:
